Leave Your Message
ADT1757-Human Anti-F9xF10 Bispecific Antibody
Hot

ADT1757-Human Anti-F9xF10 Bispecific Antibody

  • Catalog Number ADT1757
  • Host CHO Cells
  • Species Human
  • Target F9xF10
  • Application FuncS

F9,  Coagulation factor IX, the pathogenic gene of hemophilia B, can restore coagulation function through gene therapy. F10, Factor X, plays a crucial role in the coagulation cascade, and mutations can lead to hereditary coagulation disorders.

 

With Alpha Lifetech, you can order bispecific antibodies when needed. We offer a flexible ordering system that allows you to place orders according to project schedules. Our efficient manufacturing and strict processes ensure timely delivery, ensuring that you can research or produce according to plan.

Products Categories
Featured Products
recommended service
quick links
Contact Us

Product Background

Emicizumab is a humanized recombinant monoclonal antibody that mimics the function of the coagulation Factor VIII and it has the capacity to bind simultaneously to activated Factor IX and Factor X. The ability of Emicizumab to bind to all these three different factors allows it to overcome immunogenicity and unstable hemostatic efficacy produced by previous Factor VII agents.

Product Specification

Catalog Number

ADT1757

Product Name

ADT1757-Human Anti-F9xF10 Bispecific Antibody

Isotype

Human IgG4 mutation-kappa

Clonity

Monoclonal

Alternate Names

Human Anti-F9 mAb, Anti-F9 Monoclonal Antibody, F9 recombinant antibody, Anti-F9 Bispecific Antibody, Human Anti-F10 mAb, F10 recombinant antibody, Anti-F10 Monoclonal Antibody, Anti-F10 Bispecific Antibody

Official Symbol

F9xF10

Target 1

F9

Gene ID 1

2158

Target 2

F10

Gene 2

2159

Species

Human

Drug Name

Emicizumab

CAS Number

1610943-06-0

Chemical Formula

C6434-H9940-N1724-O2047-S45

Product Description

Emicizumab is an antibody against Factor IXa and Factor X used to treat hemophilia A.

Mechanism of Action

Emicizumab exerts its action by performing the function of the coagulation Factor VIII without presenting a structural homology. It presents a dual specificity which allows it to bind to both the Factor IXa and Factor X, performing the required bridging activity for the launch of the coagulation cascade.

Metabolism

Emicizumab is a monoclonal antibody and thus, it is thought to be internalized in endothelial cells bound to Fc receptor and rescued from metabolism by recycling. Later, they are degraded in the reticuloendothelial system to small peptides and amino acids which can be used for de-novo protein synthesis.

Molecular Weight

145.6 KDa

Endotoxin

<1EU/mg. Determined by the LAL method.

Sterility

0.2 μM filtered.

Expression Host

CHO Cells

Size

1mg,5mg,50mg,100mg

Research Area

Cancer

Application

FuncS

Purity

>90%

Concentration

Batch dependent

Buffer

Supplied in PBS, pH 7.4,Contains no stabilizers or preservatives

Recommended Dilution Buffer

ABDB-1002 or PBS, pH 7.4, Contains no stabilizers or preservatives.

Storage

2 weeks, 2-8℃ under sterile conditions after reconstitution. Avoid repeated freeze-thaw. -80°C for one-year storage.

Shipping Condition

Shipped on ice packs.

Protocol Information

Since applications vary, each investigator should use the application references as a guide to help estimate the appropriate dose or concentration. The dose or concentration can be further optimized experimentally in a dose-response or titration experiment. 

Note

For Research Use Only!

Reference

1. Uchida N, Sambe T, Yoneyama K, Fukazawa N, Kawanishi T, Kobayashi S, Shima M: A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects. Blood. 2016 Mar 31;127(13):1633-41. doi: 10.1182/blood-2015-06-650226. Epub 2015 Dec 1.
2. Shima M, Hanabusa H, Taki M, Matsushita T, Sato T, Fukutake K, Fukazawa N, Yoneyama K, Yoshida H, Nogami K: Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A. N Engl J Med. 2016 May 26;374(21):2044-53. doi: 10.1056/NEJMoa1511769. 

 

FAQ

Leave Your Message